The Arab Health Exhibition is the largest and most comprehensive gathering for the healthcare industry in the MENA (the Middle East and North Africa) region. It first took place in Dubai, the United Arab Emirates in 1975 and is now recognized as the second-largest healthcare exhibition and congress in the world and the largest in the Middle East. It offers important opportunities to build relationships within the healthcare industry, to showcase progress and achievement in the sector, and to explore new opportunities with stakeholders in the healthcare field. Healthcare industry representatives attend from the Middle East, Asia, Europe, and the US. The Exhibition is supported by the UAE Ministry of Health, the Abu Dhabi Health Authority, the Dubai Health Authority and the Dubai Healthcare City Authority.
Sarasota, Fl-based INVO Bioscience, Inc. (IVOB) is a medical device company focused on creating simplified, lower-cost treatments for patients diagnosed with infertility. Their solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Their lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Their mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care.
INVO Bioscience recently announced that it will attend the 45th Edition of Arab Health Exhibition and Congress on January 27-30, 2020 at the Dubai World Trade Centre in Dubai, UAE. The Company will showcase the INVOcell system, a novel fertility treatment that uses a woman’s own body as a natural incubator for the incubation of eggs and sperm during fertilization and early embryo development. The process is cost-effective, has shown comparable pregnancy rates to IVF in retrospect data, and in the Company’s opinion has the ability to increase patient access to care. With its unique ability to utilize the woman’s own body as a natural incubator, the INVOcell system can help eliminate the need for costly infrastructure and overhead associated with IVF, one of the primary hindering factors to fertility treatment across the world.
INVO Bioscience has recently signed commercialization agreements for the United States, parts of Africa, and Eurasia, as well as, an announced joint venture to open INVOcell dedicated centers in India.
“Following the successful commercial launch of INVOcell in the United States in 2019, we are developing agreements across the world for the future commercialization of INVOcell,” commented Pressly Ahammed, Director of International Business Development for INVO Bioscience. “We believe the INVOcell solution is ideally suited for the vastly underserved MENA region in that it addresses cost and access to treatment, two of the primary hindering factors of existing infertility treatments. I look forward to discussing upcoming opportunities in the MENA region at the Arab Health Congress.”
The Company believes the worldwide fertility treatment market is severely underserved with only 1% to 2% of the estimated 150 million infertile couples being treated.
To learn more about INVO Bioscience (IVOB) and to track its progress daily, please visit the Vista Partners INVO Bioscience Dedicated Research Page by clicking here.